You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. High-Resolution, Spinal Cord Stimulation for Non-Opioid Treatment of Neuropathic Pain

    SBC: MICRO-LEADS INC            Topic: 000

    In this SBIR FastTrack proposal, Micro-Leads will develop HD64—a high-resolution, 64- channel spinal cord stimulation therapy to provide more pain relief with greater specificity for those suffering from chronic neuropathic pain and opioid dependence. Over 25 million in the U.S. suffer from debilitating pain in the trunk and extremities and 55% depend on opioids to ease their suffering. Opioid a ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Cartilage Regeneration with Tunable Inflammation Resistance

    SBC: Cytex Therapeutics, Inc.            Topic: R

    Abstract: Femoroacetabular impingement or FAI is a commonly diagnosed condition affecting a younger patient population than the general osteoarthritis (OA) population. Untreated, FAI invariably leads to OA and, ultimately, total hip arthroplasty (THA). The fact that most FAI diagnoses are made in patients under the age of 40, with many in their late teens and twenties, makes FAI all the more clini ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Daily and Localized NSAID Sonophoresis for Symptomatic Treatment of Knee Osteoarthritis

    SBC: Zetroz Systems LLC            Topic: R

    Project Summary: Osteoarthritis (OA) is the most common type of arthritis, affecting over 30 million adults in the United States in 2015 and represents over 25% of medical office visits according to the Centers for Disease Control and Prevention and the National Institutes of Health. Over 40% of individuals over 65 have symptomatic OA and reduced mobility due to the disease. OA pain is often mitig ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB

    SBC: CELLF-BIO LLC            Topic: 300

    Project Summary/Abstract:Fecal incontinence (FI), the involuntary soiling of various amounts of liquid and solid stool, is often devastating from a social, psychological, and hygiene perspective. Men and women suffer from FI equally with a range of 2 - 6% in people aged 20 - 30 years. The prevalence increases to over 15% in people older than 70 years1. FI may result from an isolated or combined lo ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. ZW800-1: The 1st Zwitterionic NIR Fluorophore for Cancer Imaging and Ureter Mapping

    SBC: Curadel, LLC            Topic: 102

    Image-guided surgery using invisible near-infrared (NIR) fluorescent light is here to stay. Multiple commercial imaging systems from Stryker, Olympus, Medtronic, and Intuitive Surgical are now available for human surgery. However, only innovative NIR fluorophores will solve major clinical problems.Curadel has invented a novel family of NIR fluorophores termed “zwitterionic,” or more precisely, ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. IND-enablingEpicardial Biopharmaceutical in the Diabetic Heart

    SBC: REGENCOR INC            Topic: NHLBI

    ABSTRACT Diabetes mellitus (DM) is caused by inadequate insulin secretion or an inability to respond appropriately to secreted insulin, which leads to chronic elevated blood sugar levels (hyperglycemia). An estimated 171 million people worldwide have DM, and the prevalence of DM will more than double over the next 2 decades. Diabetic patients have increased rates, severity, and complexity of ather ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Long-acting PTH for hypoparathyroidism

    SBC: EXTEND BIOSCIENCES INC            Topic: NIDDK

    Project Summary Hypoparathyroidism is a rare disease that results from a deficiency or inability to make sufficient amounts of parathyroid hormonePTHUntreated or inadequately treated hypoparathyroidism leads to clinically significant mineral related metabolic issues including hypocalcemiawhich leads to heart arrhythmiasspasms of the vocal cordsand seizuresCurrent management of the disease for the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. IND-Enabling Pre-clinical Development of Modified P8 for the Treatment of Alzheimer's Disease

    SBC: CENNA BIOSCIENCES INC            Topic: NIA

    SummaryThe parent Commercialization Readiness Program grant was to conduct studies necessary to support regulatory submissions relating to pre-clinical development of Cenna’s peptide drug candidate mP8. mP8 is being developed as a new, first-in-class peptide drug for the treatment of Alzheimer’s disease. The funded grant builds on the substantial progress made under the previously funded SBIR ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. TDP-43 aggregation inhibitors for the treatment of ALS

    SBC: Aquinnah Pharmaceuticals Inc.            Topic: 105

    Abstract Amyotrophic Lateral SclerosisALSis a universally fatal neurodegenerative disease that afflicts overout of everyindividualsProtein aggregation has been implicated as a primary driving force in ALS and multiple other neurodegenerative illnessesTDPis the principle component of the protein aggregates in ALSand TDPalso stands out as the only genetically defined ALS mutant gene that is also the ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases

    SBC: Potrero Hill Therapeutics            Topic: 200

    NIH SBIR Phase 2B Title: Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic DiseasesPotrero Hill Therapeutics Project Summary/Abstract:Despite the current FDA-approved glucose-lowering agents, the prevalence of type 2 diabetes (T2D) and its complications continues to reach epidemic proportions. Globally, 387 million people have overt diabetes, and the prevalence ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government